About: Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://fb.cuni.cz/file/5667/FB2013A0002.pdf
Description	Anti-VEGF therapy dramatically improved the outcome of patients with renal cancer and other advanced malignancies, but may be complicated by proteinuria and hypertension. VEGF is indispensable for the normal development of glomerulus and preservation of glomerular filtration barrier. Interference with its action may result in damage to glomerular endothelial cells and (in severe cases) in renal thrombotic microangiopathy. Blood pressure and proteinuria (using dipstick) should be assessed in all patients before starting anti-VEGF therapy and regularly monitored during the treatment. Patients with severe proteinuria and/or impaired renal function should be referred to the nephrologist for further work-up. Hypertension caused by anti-VEGF therapy can be effectively treated; progression of proteinuria and/or renal dysfunction may require tapering, or even withdrawal of anti-VEGF treatment. Anti-VEGF therapy dramatically improved the outcome of patients with renal cancer and other advanced malignancies, but may be complicated by proteinuria and hypertension. VEGF is indispensable for the normal development of glomerulus and preservation of glomerular filtration barrier. Interference with its action may result in damage to glomerular endothelial cells and (in severe cases) in renal thrombotic microangiopathy. Blood pressure and proteinuria (using dipstick) should be assessed in all patients before starting anti-VEGF therapy and regularly monitored during the treatment. Patients with severe proteinuria and/or impaired renal function should be referred to the nephrologist for further work-up. Hypertension caused by anti-VEGF therapy can be effectively treated; progression of proteinuria and/or renal dysfunction may require tapering, or even withdrawal of anti-VEGF treatment. (en)
Title	Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management (en)
skos:prefLabel	Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management (en)
skos:notation	RIV/00064165:_____/13:10195716!RIV14-MZ0-00064165
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Tesař, Vladimír Tesařová, Petra
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Všeobecná fakultní nemocnice v Praze / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	100530
http://linked.open...ai/riv/idVysledku	RIV/00064165:_____/13:10195716
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	sorafenib; sunitinib; bevacizumab; hypertension; proteinuria; VEGF inhibition (en)
http://linked.open.../riv/klicoveSlovo	VEGF inhibition sunitinib bevacizumab hypertension - ischaemic heart disease - cardiac failure - vitamin D sorafenib proteinuria
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[2F36CC0BE1AA]
http://linked.open...i/riv/nazevZdroje	Folia Biologica
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	2 (xsd:int)
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	59
http://linked.open...iv/tvurceVysledku	Tesař, Vladimír Tesařová, Petra
http://linked.open...ain/vavai/riv/wos	000326215200002
issn	0015-5500
number of pages	11 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software